呋塞米与示踪剂选择对PSMA PET/CT中尿液活性及膀胱周围伪影的影响:单中心回顾性研究
该单中心回顾性研究纳入202名接受PSMA PET/CT分期的前列腺癌男性,比较使用68Ga-PSMA-11或18F-DCFPyL时联用或不联用10mg静脉呋塞米对膀胱和输尿管SUVmax及膀胱周围伪影的影响。结果显示18F-DCFPyL组尿液活性和膀胱周围伪影发生率高于68Ga-PSMA-11组,呋塞米可有效降低尿液活性,在18F-DCFPyL PET/CT中尤其有利。
要点
- 18F-DCFPyL较68Ga-PSMA-11尿液活性更高,膀胱周围伪影更常见。
- 联用10mg静脉呋塞米可有效降低膀胱和输尿管尿液活性。
- 呋塞米降低尿液活性的作用在18F-DCFPyL PET/CT中尤其有利。
核心结论
- 与68Ga-PSMA-11 PET/CT相比,18F-DCFPyL PET/CT中尿液活性增加且膀胱周围伪影发生率更高。
- 使用10mg静脉呋塞米进行强制利尿可有效降低尿液活性,在18F-DCFPyL PET/CT中尤其有利。
研究设计与样本
- 单中心回顾性研究,四个队列共202名接受PSMA PET/CT分期前列腺癌的男性。
- G-组使用68Ga-PSMA-11示踪剂且不联用呋塞米,G+组联用10mg静脉呋塞米(与示踪剂同时给药),F-组使用18F-DCFPyL且不联用呋塞米,F+组联用呋塞米。
- 比较各队列膀胱和输尿管SUVmax以及膀胱周围伪影的存在、类型和严重程度,并在考虑生物分布时间差异的情况下确定呋塞米和示踪剂选择的影响。
主要发现
- 输尿管中位SUVmax在G-组为6.4,G+组为4.5,F-组为8.1,F+组为6.0,总体差异显著(p < 0.001),G+与F-之间及F-与F+之间差异显著(p分别 < 0.001和0.019)。
- 呋塞米和示踪剂选择对膀胱SUVmax有显著影响(p分别 < 0.001和p = 0.001),呋塞米对输尿管SUVmax有显著影响(p < 0.001),而生物分布时间差异对这些结果无显著影响。
- 膀胱周围伪影存在于42/202(21%)患者中,在F-队列中显著更频繁,在G+队列中显著更少(p分别 = 0.001和p < 0.001)。
- 膀胱周围伪影与膀胱SUVmax呈直接正相关(p = 0.033)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High urinary activity in urinary bladder and ureters may hamper interpretation of prostate cancer and regional nodal metastases in prostate-specific membrane antigen (PSMA) PET/CT. The goal of this study was to assess effects of furosemide and choice of tracer on urinary activity in the bladder and ureters, as well as on occurrence of peri-bladder artefacts in PET/CT. METHODS: Four cohorts with a total of 202 men staged with PSMA PET/CT for prostate cancer received either 68Ga-PSMA-11 as tracer, with (cohort G+) or without 10mg intravenous furosemide (G-) concurrent with tracer, or 18F-DCFPyL with (F+) or without furosemide (F-). SUVmax of bladder and ureters, presence, type, and severity of peri-bladder artefacts were compared between cohorts. The influence of furosemide and choice of tracer was determined while taking differences in biodistribution time into account. RESULTS: Median SUVmax bladder was 43,5; 14,8; 61,7 and 22,8 in cohorts G-, G+, F- and F+, respectively, resulting in significant overall (p < 0.001) and between cohort differences (p adjusted < 0.001 to 0.003) except between G- and F+. Median SUVmax ureter was 6.4; 4.5; 8.1 and 6.0 in cohorts G-, G+, F- and F+, respectively, resulting in significant overall (p < 0.001) and between cohort differences for G+ : F- and F- : F+ (p < 0.001, respectively, 0.019). Significant effects of furosemide and choice of tracer on SUVmax bladder (p < 0.001 resp. p = 0.001) and of furosemide on SUVmax ureter (p < 0.001) were found, whereas differences in biodistribution time had not impacted these results significantly. Peri-bladder artefacts were present in 42/202 (21%) patients and were significantly more frequent in the F- cohort, respectively, less frequent in the G+ cohort (p = 0.001 resp. p < 0.001). Peri-bladder artefacts had a direct positive correlation with SUVmax bladder (p = 0.033). CONCLUSIONS: Increased urinary activity and higher incidence of peri-bladder artefacts were found in 18F-DCFPyL compared to 68Ga-PSMA-11 PET/CT. Effective reduction of urinary activity may be reached through forced diuresis using 10mg intravenous furosemide, which is especially advantageous in 18F-DCFPyL PET/CT.
引用
- Donswijk ML, Wondergem M, de Wit-van der Veen L, et al. Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study. EJNMMI Res. 2022. PMID: 35895129. doi:10.1186/s13550-022-00913-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。